Jessica Nye

1 week ago | rheumatologyadvisor.com | Jessica Nye

Icotrokinra is associated with significantly higher skin clearance and has a favorable safety profile for the treatment of moderate to severe plaque psoriasis when compared with placebo, according to study results presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting, held in Orlando, Florida from March 7 to 11. The first-in-class, targeted oral peptide icotrokinra selectively binds the receptor for interleukin (IL)-23, which inhibits IL-23 signaling.

1 week ago | endocrinologyadvisor.com | Jessica Nye

Tirzepatide is associated with longer continuous glycemic control than placebo or active comparators in type 2 diabetes (T2D). These findings, from a post hoc analysis, were published in Diabetes, Obesity & Metabolism. The SURPASS 1 through 5 studies were phase 3 clinical trials in which researchers compared the efficacy of 5, 10, or 15 mg tirzepatide with placebo, 1 mg semaglutide, insulin degludec, or insulin glargine for 40 or 52 weeks.

1 week ago | endocrinologyadvisor.com | Jessica Nye

Receiving gender-affirming hormone therapy (GAHT) is associated with lower rates of moderate to severe depressive symptoms among transgender, nonbinary, and gender diverse (TGD) adults in the United States (US), according to study findings published in JAMA Network Open. Adults who are TGD experience a depression rate that is 2- to 4-times higher than the general population.

1 week ago | thecardiologyadvisor.com | Jessica Nye

The American Heart Association released a scientific statement in Circulation about sociodemographic disparities in the management and outcomes of pulmonary embolism (PE). In the United States (US), PE-associated mortality rates have increased between 2008 and 2018. Black patients are more likely to be hospitalized with PE than White patients, whereas Hispanic patients are less likely to have venous thromboembolism (VTE) than White patients.

1 week ago | gastroenterologyadvisor.com | Jessica Nye

Hypothyroidism concomitant with inflammatory bowel disease (IBD) was associated with increased risk for additional extraintestinal manifestations (EIMs) and greater health care use compared with having IBD alone, according to results of a study published in Digestive Diseases and Sciences. While the thyroid is the most commonly affected organ in patients with autoimmune diseases, such as IBD, the effects of concomitant hypothyroidism on patient outcomes is not fully understood.